Home
IPO Review by Dilip Davda
Menu
Home
Markets
IPO Review by Dilip Davda
India Inc
Economy and Politics
Global Markets
Pages
Home
IPO Review by Dilip Davda
Categories
Home
Markets
IPO Review by Dilip Davda
India Inc
Economy and Politics
Global Markets
Tag:
Evonile Pharma
IPO Review by Dilip Davda
Evonile Pharma Rights Issue Review: Should Investors Subscribe?
Dilip Davda
—
November 22, 2026
add comment
Evonile Pharma’s ₹860 rights issue, covering the 5:12 entitlement, recent losses, share price performance and debt reduction. Evonile Pharma Ltd is coming out with its Rights Issue (RI) of 10287832 equity shares...
Read more »